Table 2.
Method of measuring LVEF and Characteristics of heart failure of included trials at baseline
| Method of measuring LVEF | NYHA I, % | NYHA II or III, % | NYHA IV, % | Average LVEF, % | % of ischemic heart failure | % of non-ischemic heart failure | |
|---|---|---|---|---|---|---|---|
| MacDonald et al.14 | Radionuclide ventriculography | 0 | 100 | 0 | 18 | 49 | 51 |
| ARC-HF16 | Radionuclide ventriculography | 0 | 100 | 0 | 23 | 33 | 67 |
| CAMTAF13 | Transthoracic echocardiography | 0 | 100 | 0 | 33 | 26 | 74 |
| AATAC12 | Not mentioned | 0 | 100 | 0 | 30 | NA | NA |
| CAMERA-MRI15 | Cardiac magnetic resonance |
0 | NA | NA | 35 | 0 | 100 |
| CASTLE-AF6 | Transthoracic echocardiography | 11 | 88 | 1 | 32 | 46 | 54 |
LVEF: left ventricular ejection fraction; NYHA: New York Heart Association Class
Trial name: AATAC: Ablation vs Amiodarone for Treatment of Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted ICD/CRTD; ARC-HF: A Randomised Trial to Assess Catheter Ablation Versus Rate Control in the Management of Persistent Atrial Fibrillation in Chronic Heart Failure; CAMTAF: Catheter Ablation Versus Medical Treatment of Atrial Fibrillation in Heart Failure; CAMERA-MRI: Catheter Ablation Versus Medical Rate control in Atrial Fibrillation and Systolic Dysfunction; CASTLE-AF: Catheter Ablation versus Standard Conventional Therapy in Patients with Left Ventricular Dysfunction and Atrial Fibrillation
CMR: cardiac magnetic resonance; NYHA: New York Heart Association; TTE: transthoracic echocardiography; SD: standard deviation